ArticleMultiple sclerosis journal - experimental, translational and clinical
Response to therapy in a cohort of patients with late-onset multiple sclerosis.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Late-onset MS (LOMS, symptom onset after age 50) remains underrepresented in clinical trials, leading to a gap in knowledge about the efficacy of disease-modifying therapies (DMTs). This study aims to evaluate treatment outcomes in relapsing LOMS. Methods: A retrospective electronic medical record study at Northwestern University analyzed patients with LOMS presenting between 2004 and 2021. Demographic, clinical, DMT, and MRI data were extracted. Statistical analyses evaluated progression based on DMT efficacy. Results: Overall, 63 patients (63% female, 76% white, median onset 55 years) were followed for a median of 7.6 years. Most patients (73%) were started on low/moderate efficacy DMTs (LET/MET). Increasing baseline EDSS was associated with an increased risk of reaching EDSS 6 ( Discussion: The effect of LET/MET DMTs is less pronounced in older adults and may not significantly impact long-term disability outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.